Investigation of factors influencing anxiety and depression symptoms after therapy in 200 patients diagnosed with primary liver cancer

对200例原发性肝癌患者治疗后焦虑和抑郁症状的影响因素进行调查

阅读:1

Abstract

BACKGROUND: Patients undergoing interventional therapy for liver cancer experience severe psychological pain and are prone to anxiety and depression. AIM: To explore factors influencing anxiety and depression symptoms in 200 patients diagnosed with primary liver cancer. METHODS: Data from 200 individuals diagnosed with primary liver cancer and admitted to the authors' hospital (January 2022 to January 2024) were divided into 2 groups according to psychological status: Normal (n = 100); and anxiety and depression (n = 100). Through a questionnaire survey of patients and their families, single and multifactor factors of anxiety and depression in the postoperative interventional treatment of patients with primary liver cancer were analyzed. RESULTS: Univariate analysis revealed no statistical differences between the 2 groups in terms of chronic disease, sex, liver function, Child grade, and age (P > 0.05). However, there were statistical differences in payment method, disease cognition, number of interventional treatments, per capita income, and educational level (P < 0.05). Multivariate logistic regression analysis revealed that educational level, per capita income, disease cognition, payment method, and number of interventional treatments were all independent factors influencing postoperative anxiety and depression symptoms after interventional therapy in patients diagnosed with primary liver cancer, and the comparisons were statistically significant (P < 0.05). CONCLUSION: Analysis of associated risk factors can strengthen the clinical screening of patients with liver cancer at high risk for postoperative anxiety and depression symptoms and improve their prognosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。